Лучшие больницы для «Hypertension Treatment» в Дубай, ОАЭ

Hypertension is defined as a sustained systolic blood pressure ≥130 mmHg and/or diastolic ≥80 mmHg (AHA/ACC 2017 guidelines) or ≥140/90 mmHg (ESC 2018 guidelines), and it represents the single largest modifiable risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and peripheral arterial disease. The underlying pathophysiology involves dysregulation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system hyperactivation, endothelial dysfunction, arterial stiffness, and sodium-volume dysregulation. In approximately 90–95% of cases, hypertension is classified as primary (essential), with no single identifiable cause; in 5–10% it is secondary, driven by identifiable etiologies including primary aldosteronism, renal artery stenosis, obstructive sleep apnea, pheochromocytoma, or Cushing's syndrome — all of which are systematically screened for at GAF Healthcare partner centers.

• Patients with newly diagnosed or poorly controlled hypertension (BP consistently >140/90 mmHg on two or more readings) seeking comprehensive evaluation and optimized medical therapy
• Individuals with suspected secondary hypertension (young patients, resistant to ≥3 medications, with clinical clues such as hypokalemia, adrenal incidentaloma, or renal bruit) requiring specialized investigation including aldosterone-to-renin ratio, renal artery Doppler, 24-hour urinary catecholamines/metanephrines, or overnight dexamethasone suppression test
• Patients with resistant hypertension (blood pressure uncontrolled despite ≥3 antihypertensive agents including a diuretic at optimal doses, with adherence confirmed) who are candidates for renal denervation or baroreflex activation therapy
• Individuals with hypertensive urgency or emergency (BP >180/120 mmHg with or without acute end-organ damage) requiring inpatient parenteral management and monitoring
• Patients with hypertension-associated target organ damage: left ventricular hypertrophy (LVMI >115 g/m² in men, >95 g/m² in women), microalbuminuria (UACR 30–300 mg/g), eGFR <60 mL/min/1.73m², or subclinical atherosclerosis on carotid intima-media thickness (CIMT) assessment
• +2 more

LIFESTYLE AND NON-PHARMACOLOGICAL INTERVENTIONS (First-Line for Stage 1 Hypertension, Adjunct for All Stages):

Structured therapeutic lifestyle modification remains the foundation of hypertension management. GAF Healthcare partner centers offer medically supervised programs including the DASH (Dietary Approaches to Stop Hypertension) dietary protocol (targeting sodium intake <2.3 g/day and increased potassium to 3.5–5 g/day), aerobic exercise prescription (150 minutes/week of moderate-intensity activity reduces systolic BP by 5–8 mmHg), weight reduction (1 mmHg systolic reduction per 1 kg lost), alcohol moderation (≤14 units/week men, ≤8 units/week women), and structured smoking cessation programs. These interventions are combined with continuous remote blood pressure monitoring platforms for real-time physician oversight.

Pharmacological Management — Stepped-care ALGORITHM:

Step 1 (Monotherapy or Dual Combination): ACE inhibitors (ramipril, perindopril) or ARBs (telmisartan, olmesartan) are first-line for patients with diabetes, CKD, or high cardiovascular risk. CCBs (amlodipine, lercanidipine) are first-line for elderly patients and those with isolated systolic hypertension. Thiazide-like diuretics (indapamide) are preferred over thiazides (hydrochlorothiazide) for superior cardiovascular outcome data.

PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel): Patients submit medical records, home blood pressure logs, current medication list, and prior investigation reports through GAF Healthcare's secure online portal. A dedicated case manager assigns a consultant cardiologist or nephrologist who reviews records and issues a preliminary treatment plan within 48 hours. Patients are advised to bring a minimum 4-week supply of current antihypertensive medications (with generic/INN names confirmed), and to continue current therapy without interruption to avoid rebound hypertension during travel. A pre-travel blood pressure target of <160/100 mmHg is required for fitness to fly on arrival.

PHASE 2 — DAY 1 TO DAY 3 (Arrival and Comprehensive Evaluation): On Day 1, patients undergo hospital admission (if inpatient evaluation) or outpatient registration. A comprehensive baseline assessment is completed: 24-hour ABPM placement, fasting bloodwork (renal panel, electrolytes, lipids, HbA1c, aldosterone-renin ratio, plasma metanephrines), urinalysis with UACR, 12-lead ECG, and a detailed clinical examination including fundoscopy. Echocardiography (transthoracic, with tissue Doppler imaging for diastolic function and LV mass index quantification) is performed on Day 1 or 2. Renal Doppler ultrasound and, if indicated, CT adrenal with fine cuts or MRI adrenal are completed by Day 2. A multidisciplinary team (cardiologist, nephrologist, endocrinologist, dietitian) case conference occurs on Day 2–3 to formulate the definitive treatment plan.

PHASE 3 — DAYS 3–7 (Treatment Initiation or Procedure): For medical management optimization: The treating physician adjusts, rationalizes, or initiates antihypertensive therapy based on investigation results, guided by individualized hemodynamic data from the ABPM. For spironolactone initiation, serum potassium and renal function are rechecked at 72 hours. Blood pressure response is assessed with daily readings. For renal denervation: The procedure is performed on Day 3–4 in the cardiac catheterization laboratory. Post-procedure observation occurs for 24 hours with continuous BP telemetry. Discharge on Day 5 with outpatient follow-up on Day 7. For laparoscopic adrenalectomy: Surgery is performed under general anesthesia (Day 4–5). Post-operative electrolytes and aldosterone levels are checked on Days 1 and 2 post-surgery. Oral intake resumes within 24 hours. Hospital discharge by Day 7–8.